Klaria enters into option agreement with Imbrium Therapeutics for the US market rights of the drug candidate Epinephrine Alginate Film for treatment of Serious Allergic Reactions
Klaria Pharmaceuticals announced today that it has signed an agreement with Imbrium Therapeutics granting it an option for an exclusive license for the United States marketing rights to the drug candidate Epinephrine Alginate Film.Klaria Pharmaceutical’s drug candidate Epinephrine Alginate Film is being developed as a treatment for serious allergic reactions, so called Anaphylactic Shock, as an alternative to currently available treatment options including EpiPen[TM]. “The Epinephrine treatments used today are auto-injection pens, originally invented in the mid-1970s. Auto-injector pens